S. Korea Celltrion’s candidate COVID-19 drug gets approval for special-case use
FILE PHOTO: The logo of Celltrion is seen at company’s headquarters in Incheon, South Korea, October 28, 2016. REUTERS/Kim Hong-Ji/File Photo
SEOUL—Doctors can administer South Korean pharmaceutical maker Celltrion Inc’s candidate COVID-19 antibody treatment to patients with life-threatening conditions, health authorities said on Tuesday.
The Ministry of Food and Drug Safety approved CT-P59 under its patient treatment scheme on Friday, its website showed.
Under the scheme, patients with life-threatening conditions and with no other means of treatment can receive drugs still undergoing clinical trials, the ministry said.
Celltrion is conducting second- and third-phase clinical trials for CT-P59, and plans to seek emergency-use approval for the treatment before year-end, a company spokesman said.
The treatment is expected to be administered to the first patients “soon,” Korea Disease Control and Prevention Agency official Kwon Jun-wook said in a briefing on Tuesday.
Article continues after this advertisementRELATED STORIES
U.S. FDA authorizes Pfizer COVID-19 vaccine for emergency use
US begins COVID -19 vaccinations as its death toll passes 300,000
For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.
